ahlam1399
02-26-2016, 06:34 PM
Rivals chase Bristol-Myers in cancer immu**therapy drug race
LONDON (Reuters) - Bristol-Myers Squibb has pulled ahead in the race to dominate the hot new cancer immu**therapy market but Merck & Co, Roche and AstraZeneca still have important opportunities to close the gap.
http://i1.wp.com/reuters.us.feedsportal.com/c/35217/f/654207/s/4ddfe7a7/sc/13/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=dQXQx88_04U:4SDZybYus3Q:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=dQXQx88_04U:4SDZybYus3Q:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=dQXQx88_04U:4SDZybYus3Q:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=dQXQx88_04U:4SDZybYus3Q:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=dQXQx88_04U:4SDZybYus3Q:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/dQXQx88_04U
LONDON (Reuters) - Bristol-Myers Squibb has pulled ahead in the race to dominate the hot new cancer immu**therapy market but Merck & Co, Roche and AstraZeneca still have important opportunities to close the gap.
http://i1.wp.com/reuters.us.feedsportal.com/c/35217/f/654207/s/4ddfe7a7/sc/13/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=dQXQx88_04U:4SDZybYus3Q:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=dQXQx88_04U:4SDZybYus3Q:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=dQXQx88_04U:4SDZybYus3Q:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=dQXQx88_04U:4SDZybYus3Q:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=dQXQx88_04U:4SDZybYus3Q:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/dQXQx88_04U